SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 81 of 94
Word Count: 1496
Character Count: 9510

Document Content:

The Company has a 401(k) plan in which employees who have met certain eligibility requirements may participate. Each eligible employee may elect to contribute to the 401(k) plan, and the Company may make discretionary contributions. The Company has recorded contributions of $27,408 and $6,929 in selling, general administration expenses for the three months ended March 31, 2026, and 2025, respectively in Note 14 – Segments The Company operates in one reportable segment, which is the development of a new product to treat heart failure. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM regularly reviews and uses consolidated net loss, as reported on our Consolidated Statements of Operations in evaluating the overall performance of the single reporting segment. As a result, the Company has determined that it has only one reportable segment. BIOVENTRIX, INC. Notes to Consolidated Financial Statements March 31, 2026 and 2025 (unaudited)

Although
the Company has generated no revenue during the reporting period, it continues to incur expenses related to research and development,
general and administrative activities, and other operational costs. The CODM uses these expense categories to assess the Company’s
performance and allocate resources.

The
accounting policies of the single segment are the same as those described in the summary of significant accounting policies. There have
been no significant changes in measurement methods during the reporting period. Geographically, the Company has no assets in a foreign
country requiring separate disclosure.

The
following table provides the significant expenses that management used to manage the one reportable segment for the three months ended
March 31:

Research
and development $	597,576 $	83,137

Selling,
general and administrative 2,088,345 967,478

Total
operating expenses $	2,685,921 $	1,050,615

Note
15 – Subsequent events

preparing the financial statements, the Company has evaluated all subsequent events and transactions for potential recognition or disclosure
through May 14, 2026, the date the financial statements were available for issuance.

April 6, 2026, the Company’s Board of Directors designated 200,000 shares of blank check preferred stock as Series A-2 preferred
stock. The Board of Directors also authorized the issuance of up to $6,000,000 in aggregate principal amount of secured convertible promissory
notes (the “Series A-2 Notes”) the repayment of which will be secured by a grant of security interest in all of the Company’s
assets which security interest will be pari passu with the security interest granted to holders of the Company’s currently outstanding
secured convertible notes in the aggregate principal amount of $10,875,000,

The
Series A-2 Notes accrue interest at the annual rate of 15% compounded quarterly and have a maturity date of December 31, 2027. The conversion
features of the Series A-2 Notes are as follows:

Qualified
Financing: In the event the Company sells shares of its equity securities while the Series A-2 Notes are outstanding in an equity
financing with total gross proceeds to the Company of $20,000,000 or more (excluding the conversion of the Series A-2 Notes and the Existing
Secured Convertible Notes) (a “Qualified Financing”), then the outstanding principal amount of the Series A-2 Notes and any
unpaid accrued interest shall automatically convert into, at the noteholder’s election, either (i) such equity securities sold
in the Qualified Financing at a conversion price equal to the price paid per share for the equity securities paid by the investors in
the Qualified Financing multiplied by 0.75, or (ii) Series A2 Preferred Stock of the Company at the price of $50.00 per share which Series
A-2 Preferred Stock is convertible into Common Stock at a rate of 10 shares of Common Stock for each 1 share of Series A-2 Preferred
Stock. The issuance of shares pursuant to the conversion of the Series A-2 Notes into equity securities issued in the Qualified Financing
shall be upon and subject to the same terms and conditions applicable to the securities sold in the Qualified Financing other than with
respect to (i) the per share liquidation preference and the conversion price for purposes of price-based anti-dilution protection which
shall be equal to the conversion price and (ii) the per share dividend which will be the same percentage of the conversion price as applied
to determine the per share dividends of new investors in the Qualified Financing.

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

March
31, 2026 and 2025

(unaudited)

Non-Qualified
Financing: In the event that the Company sells shares of its equity securities while the Series A-2 Notes are outstanding in an equity
financing with total gross proceeds to the Company of less than $20,000,000 (excluding the conversion of the Series A-2 Notes and the
Existing Convertible Notes) (a “NonQualified Financing”), then the outstanding principal amount of the Series A-2 Notes and
any unpaid accrued interest shall at the option of the noteholder either remain in place as a convertible note or convert into, at the
noteholder’s election, either (i) such equity securities sold in the Non-Qualified Financing at a conversion price equal to the
price paid per share for the equity securities paid by the investors in the Qualified Financing multiplied by 0.75, or (ii) Series A-2
Preferred Stock of the Company at the price of $50.00 per share which Series A-2 Preferred Stock is convertible into Common Stock at
a rate of 10 shares of Common Stock for each 1 share of Series A-2 Preferred Stock. The issuance of shares pursuant to the conversion
of the Series A-2 Notes into equity securities issued in the Non-Qualified Financing shall be upon and subject to the same terms and
conditions applicable to the securities sold in the Non-Qualified Financing other than with respect to (i) the per share liquidation
preference and the conversion price for purposes of price-based anti-dilution protection which shall be equal to the conversion price
and (ii) the per share dividend which will be the same percentage of the conversion price as applied to determine the per share dividends
of new investors in the NonQualified Financing.

Qualified
IPO: In the event of a sale of shares of common stock of the Company to the public in a public offering pursuant to an effective
registration statement under the Securities Act resulting in at least $7,500,000 of gross proceeds, net of the underwriting discount
and commissions, to the Company and in connection with such offering the Common Stock is listed for trading on the Nasdaq Stock Market’s
National Market, the New York Stock Exchange or another exchange or marketplace approved the Board of Directors (a “Qualified IPO”),
then the Series A-2 Notes shall automatically convert into shares of Series A-2 Preferred Stock of the Company at the price of $50.00
per share immediately prior to the Qualified IPO which Series A2 Preferred Stock shares will then be subject to mandatory conversion
into Common Stock as provided in the Certificate of Designations of the Series A-2 Preferred Stock.

Change
of Control: If the Company consummates a change of control while the Series A-2 Notes are outstanding, the Company shall repay the
noteholders the amount of two times (2x) the outstanding principal amount of the Series A-2 Notes and any unpaid accrued interest; provided,
however, in the alternative, and at the option of the noteholder, the noteholder may elect to convert the outstanding principal balance
of the 2026 Secured Convertible Note and any unpaid accrued interest into shares of the Company’s Series A-2 Preferred Stock at
the price of $50.00 per share which Series A-2 Preferred Stock is convertible into Common Stock at a rate of 10 shares of Common Stock
for each 1 share of Series A-2 Preferred Stock.

Maturity Date: In the event that a Qualified Financing, a NonQualified, a Qualified IPO or a change of control has not occurred on or
before the Maturity Date, then, at the option of the noteholder, the outstanding principal amount of the 2026 Secured Convertible Note
and any unpaid accrued interest may be converted into shares of the Company’s Series A-2 Preferred Stock at a price of $50.00 per
share which Series A-2 Preferred Stock is convertible into Common Stock at a rate of 10 shares of Common Stock for each 1 share of Series
A-2 Preferred Stock, or the Company shall repay the noteholders the amount of two times (2x) the outstanding principal amount of the
Series A-2 Notes and any unpaid accrued interest.

On April 17, 2026, entities controlled by an officer
purchased $255,000 of Series A-2 Notes.

On April 21, 2026, entities controlled by a director purchased $200,000
of Series A-2 Notes.

Through
May 14, 2026, the Company raised $805,000 of Series A-2 Notes.

INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS

BIOVENTRIX,
INC.

CONSOLIDATED
FINANCIAL STATEMENTS

Years
Ended December 31, 2025 and 2024

and
Report of Independent Registered Accounting Firm

BIOVENTRIX,
INC.

CONSOLIDATED
FINANCIAL STATEMENTS

Years
Ended December 31, 2025 and 2024

Table
of Contents

Report
of Independent Registered Accounting Firm	F- 20

Consolidated
Financial Statements:

Consolidated
Balance Sheets	F- 21

Consolidated
Statements of Operations	F-22

Consolidated
Statements of Changes in Stockholders’ Deficit	F-23

Consolidated
Statements of Cash Flows	F- 24